GENZ (GENZYME CORPORATI)

Zecco.com
All Pro Portfolios with GENZ

People owning GENZ also tend to own:: LRCXWRLDAMGNDNAAMZNBLUDHPQ

All Do-It-Yourself Portfolios with GENZ
  • News For Selected Stock
  • Related stories on theStreet.com
  • 11/19/08
  • 11/14/08
  • blogs related to etf's
  • No blogs found
  •  

Why I Love This Stock

By:Pro

Date:11 30 -1

The Week's Shocker Stock: Stephanie Link, director of research for the Action Alerts PLUS Portfolio, unveils the shocker stock of the week and explains why it's safe even without a dividend.
Click here to watch the video.

Not yet rated
Rate now:

By:barrons3

Date:11 01 08

Pesek also likes Cambridge, Mass.-based Genzyme (GENZ), a biotech outfit focused on diseases stemming from enzyme disorders. "Its small nichey markets provide an opportunity to raise prices," Pesek says, noting that many of its pipeline products -- such as Myozyme, for treating often-fatal Pompe disease, which can affect muscles and the heart, and Mozibil, used to increase stem-cell counts in transplants -- benefit from orphan-drug status. Campath, for multiple sclerosis, differs because it has a potentially enormous market. The National MS Society estimates that about 200 Americans are diagnosed with this auto-immune disease every week. Overall, there are about 400,000 people in the U.S. and more than 2.5 million people worldwide suffering from MS. "Management believes they can achieve a compound annual growth rate in earnings per share of 20% from 2007-2010, and if pipeline products are successful that will be even better," Pesek says. He added to his Genzyme stake in the summer of 2007 when the stock was trading in the low to mid-60s. More recently, it's been trading at 70.20. The consensus estimate for Genzyme's EPS is $3.97 in '08, $4.73 in '09 and $5.55 in '10. Its price-to-earnings multiple works out to about 15 times '09 estimates.

Not yet rated
Rate now:

By:barrons3

Date:09 18 08

The derivatives are more powerful than the stocks they encompass -- Nasdaq or S&P futures -- but they are not more powerful than the companies themselves. Genzyme (GENZ), Gilead (GILD), Hologic (HOLX), Starbucks (SBUX), they will all get killed. Is that right? I don't think so.

Not yet rated
Rate now:

By:Pro

Date:11 30 -1

BofA initiated Genzyme (GENZ) as a Buy with $90 price target, PEG of 1.1 and 2009 EPS of $4.68 based on a 3-year CAGR of 17%.

Not yet rated
Rate now:

By:stockerblog

Date:05 10 08

products and therapies relating to renal, therapeutics, transplants, biosurgery, and genetics

Not yet rated
Rate now:

By:barrons2

Date:04 02 08

check out Genzyme (GENZ) and Isis (ISIS) for their diabetes and cholesterol franchises.

Not yet rated
Rate now:

By:JAEdwards

Date:03 31 08

Biotech medical player

Not yet rated
Rate now:

By:moab_troy

Date:03 02 08

Great future

Not yet rated
Rate now:

By:gvphubli

Date:01 28 08

Earnings Stability Rating: 3. Biotech large cap’s industry group is one of the best-performing over the past six months. Five-year earnings growth rate: 27%.

Not yet rated
Rate now:

By:Jr Birdman

Date:01 14 08

made money

Not yet rated
Rate now:

Why I Hate This Stock

By:Adrian Smith

Date:02 26 08

Lost many dollars

Not yet rated
Rate now:

By:great stock picker

Date:09 10 07

out classed by competition

Not yet rated
Rate now:
Add Your Comments  
Stock GENZ
Allowed HTML tags: <a><b><i><img>
  Login to post your comments
Top Nasdaq Short-Squeeze Plays

The stock market, as measured by Nasdaq, is trading near its lowest point in the last several years. When the market drops as much as it has, it creates noteworthy short sq...

12.02.08 | 12:11 PM
Top Dividend Plays for the Week

Even though Thanksgiving week was a short trading week, there were still plenty of companies that raised their dividends -- from food companies to water companies to medica...

12.01.08 | 16:30 PM
The Santa Portfolio -- Updated

The retailer stocks have been hammered so hard, due to low sales expectations for the holiday season, that the metrics on these stocks have become very favorable. If th...

12.01.08 | 11:29 AM
Rocket Stocks for the Week

The time to be greedy in the capital markets is when everyone else is fearful. Fortunately, we loaded up on the highest beta momentum names we could find last week, and we...

12.01.08 | 09:09 AM
more articles
General market Technical Analysi...
11.14.07 | 22:55 PM From author ZackAttack
Reading charts
08.16.08 | 09:03 AM From author Peter near Matanzas Inlet
Kabirms Korner
04.22.08 | 23:15 PM From author kabirm
more forums
today 's lists
Latest Activist Situations

Here are the latest Activist or "13D" situations from the StreetInsider.com 13D Tracker page found at: http://www.13dtracker.blogspot.com/.... more

Stocks Most Likely to Disappoint

This list consists of stocks that have had very nice up move over the last year and may be poised to disappoint going forward. The basis for the list is as follows: 52 w... more

Mid-Cap Value Plays

This is a screen of mid cap stocks, i.e. with market capitalizations between $1 billion and $5 billion that also have a P/E less than or equal to 10 and a quick ratio of gr... more